These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10391667)

  • 1. Down-regulation of the pharmacokinetic-pharmacodynamic response to interleukin-12 during long-term administration to patients with renal cell carcinoma and evaluation of the mechanism of this "adaptive response" in mice.
    Rakhit A; Yeon MM; Ferrante J; Fettner S; Nadeau R; Motzer R; Bukowski R; Carvajal DM; Wilkinson VL; Presky DH; Magram J; Gately MK
    Clin Pharmacol Ther; 1999 Jun; 65(6):615-29. PubMed ID: 10391667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
    Portielje JE; Kruit WH; Schuler M; Beck J; Lamers CH; Stoter G; Huber C; de Boer-Dennert M; Rakhit A; Bolhuis RL; Aulitzky WE
    Clin Cancer Res; 1999 Dec; 5(12):3983-9. PubMed ID: 10632329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Schwartz LH; Olencki T; Malone TM; Sandstrom K; Nadeau R; Parmar H; Bukowski R
    Clin Cancer Res; 1998 May; 4(5):1183-91. PubMed ID: 9607576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-gamma and CXC chemokine induction by interleukin 12 in renal cell carcinoma.
    Bukowski RM; Rayman P; Molto L; Tannenbaum CS; Olencki T; Peereboom D; Tubbs R; McLain D; Budd GT; Griffin T; Novick A; Hamilton TA; Finke J
    Clin Cancer Res; 1999 Oct; 5(10):2780-9. PubMed ID: 10537342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
    Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
    Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down-regulation of IL-18 receptor in cancer patients: its clinical significance.
    Kobashi K; Iwagaki H; Yoshino T; Morimoto Y; Kohka H; Kodama M; Nishibori M; Akagi T; Tanaka N
    Anticancer Res; 2001; 21(5):3285-93. PubMed ID: 11848485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-induced dysfunction in interleukin-2 production and interleukin-2 receptor signaling: a mechanism of immune escape.
    Rayman P; Uzzo RG; Kolenko V; Bloom T; Cathcart MK; Molto L; Novick AC; Bukowski RM; Hamilton T; Finke JH
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S81-7. PubMed ID: 10685665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment.
    Teuber G; Rossol S; Lee JH; Dietrich CF; Zeuzem S
    Z Gastroenterol; 2002 Jul; 40(7):487-95. PubMed ID: 12122596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.
    Zeuzem S; Hopf U; Carreno V; Diago M; Shiffman M; Grüne S; Dudley FJ; Rakhit A; Rittweger K; Yap SH; Koff RS; Thomas HC
    Hepatology; 1999 Apr; 29(4):1280-7. PubMed ID: 10094976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity.
    Matsuse H; Kong X; Hu J; Wolf SF; Lockey RF; Mohapatra SS
    Int Immunopharmacol; 2003 Apr; 3(4):457-68. PubMed ID: 12689651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autocrine regulation of IL-12 receptor expression is independent of secondary IFN-gamma secretion and not restricted to T and NK cells.
    Thibodeaux DK; Hunter SE; Waldburger KE; Bliss JL; Trepicchio WL; Sypek JP; Dunussi-Joannopoulos K; Goldman SJ; Leonard JP
    J Immunol; 1999 Nov; 163(10):5257-64. PubMed ID: 10553047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IL-12 stimulates an antiviral type 1 cytokine response but lacks adjuvant activity in IFN-gamma-receptor-deficient mice.
    Schijns VE; Haagmans BL; Horzinek MC
    J Immunol; 1995 Sep; 155(5):2525-32. PubMed ID: 7650382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-12 and -18 levels in peritoneal dialysate effluent correlate with the outcome of peritonitis in patients undergoing peritoneal dialysis: implications for the Type I/Type II T-cell immune response.
    Wang HH; Lin CY
    Am J Kidney Dis; 2005 Aug; 46(2):328-38. PubMed ID: 16112053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+T cells directly induces apoptosis of mouse hepatocellular carcinoma.
    Komita H; Homma S; Saotome H; Zeniya M; Ohno T; Toda G
    J Hepatol; 2006 Nov; 45(5):662-72. PubMed ID: 16935390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
    Propper DJ; Chao D; Braybrooke JP; Bahl P; Thavasu P; Balkwill F; Turley H; Dobbs N; Gatter K; Talbot DC; Harris AL; Ganesan TS
    Clin Cancer Res; 2003 Jan; 9(1):84-92. PubMed ID: 12538455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
    J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma.
    Motzer RJ; Rakhit A; Thompson JA; Nemunaitis J; Murphy BA; Ellerhorst J; Schwartz LH; Berg WJ; Bukowski RM
    J Interferon Cytokine Res; 2001 Apr; 21(4):257-63. PubMed ID: 11359657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [TH1 response in the experimental infection with Trypanosoma cruzi].
    Cardoni RL; Antúnez MI; Abrami AA
    Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.